Stimulant Dependence Risk and Your Genetics

Stimulant dependence is a substance use condition in which the need to use stimulants — including amphetamines and cocaine — persists despite serious harm, and where genetic variation influences individual susceptibility.[¹] Research has linked variants near NRXN1, GNAO1, CPVL, and SLC25A16 to liability for this condition, with findings also pointing to genetic overlap with alcohol use disorders, ADHD, and anxiety.[¹] Below: how these genes affect brain signaling, the research evidence, and what it means for understanding your profile.

What is stimulant dependence?

Stimulant dependence — also referred to as stimulant use disorder — develops when repeated use of substances such as cocaine, methamphetamine, or prescription amphetamines alters brain chemistry in ways that make stopping extremely difficult. The defining feature is a compulsive drive to use despite mounting negative consequences in relationships, health, employment, and daily functioning. Stimulants achieve their effects primarily by flooding the brain's reward pathways with dopamine and other chemical signals, creating powerfully reinforcing experiences.

What makes some people substantially more vulnerable than others is partly encoded in genetics. Family and twin studies have long established that liability to substance use disorders clusters in families beyond what shared environments alone can explain. Genome-wide research has now identified specific chromosomal regions where common variants associate with elevated risk — helping researchers map the biological pathways that underlie individual differences in susceptibility.

Stimulant dependence frequently co-occurs with other conditions, including ADHD, anxiety, and depression. The genetic evidence suggests this overlap is partly biological: many of the same inherited pathways that increase vulnerability to one condition appear to increase vulnerability to others.

The genetics behind stimulant dependence

Four genes stand out in the current genetic evidence base for stimulant dependence.

NRXN1 (neurexin 1) encodes a presynaptic adhesion molecule — a protein at the surface of nerve cells that physically connects them to neighboring cells across a synapse. Neurexins partner with postsynaptic proteins called neuroligins to stabilize and organize synaptic connections. NRXN1 is expressed broadly across the brain, including in the reward circuitry that dopamine activates during pleasurable experiences. Variants near NRXN1 have emerged in research on stimulant dependence,[¹] echoing their association with other conditions involving disrupted neurodevelopment and reward signaling.

GNAO1 (guanine nucleotide-binding protein subunit alpha-O) encodes the alpha subunit of the Go heterotrimeric G-protein complex — a molecular switch that carries inhibitory signals between activated receptors and downstream effector systems in neurons. When neurotransmitters bind their receptors, Go proteins help translate that binding into intracellular responses that regulate neuronal excitability and downstream signaling. The integrity of this signaling is essential for maintaining balanced reward responses.[¹]

CPVL (carboxypeptidase vitellogenic-like) encodes a serine carboxypeptidase — an enzyme that removes amino acids from the ends of proteins. Studies of prefrontal cortex gene expression have found that CPVL levels are elevated in people who used cocaine, cannabis, and phencyclidine.[¹] The prefrontal cortex is the brain region most central to decision-making, impulse regulation, and executive control — areas that are measurably disrupted by chronic stimulant use. CPVL's prominence in this tissue may reflect a shared biological response to stimulant exposure.

SLC25A16 is the highest-confidence gene from fine-mapping analysis of stimulant dependence genome-wide data. It encodes a mitochondrial carrier protein — a membrane-spanning protein that transports substrates across the inner mitochondrial membrane to support cellular energy production. The strongest genome-wide significant signal in published stimulant dependence research sits near SLC25A16 on chromosome 10, and emerged most clearly in people of African ancestry.[¹]

The genome-wide research also found significant enrichment with nicotinic acetylcholine receptor-related genes — proteins that respond to nicotine and play roles in reinforcement learning across multiple substance types.[¹] This points toward a shared neural substrate for addictive reinforcement that involves cholinergic pathways alongside dopaminergic ones.

3.70× greater odds of stimulant dependence in African-ancestry individuals carrying the lead SLC25A16 variant — the strongest genome-wide significant signal from a multi-ancestry discovery and replication study of stimulant use disorder.^[¹]

What the research says

Research base: Moderate. The published genetic literature on stimulant dependence is meaningful but less extensive than for conditions with decades of large-cohort study.

Cox et al. (2021) conducted a genome-wide study of stimulant dependence in discovery cohorts spanning both African-ancestry and European-ancestry individuals, followed by an independent replication cohort. One variant near SLC25A16 reached genome-wide significance in African-ancestry individuals, with additional suggestive signals at other loci. The analysis also identified statistically significant genetic overlap — called pleiotropy — between stimulant dependence and alcohol dependence, anxiety disorder, and ADHD.[¹]

Independent replication confirmed core signals — the discovery and replication cohorts together spanned African-ancestry and European-ancestry individuals, and the study demonstrated significant genetic overlap between stimulant dependence, alcohol dependence, anxiety, and ADHD.^[¹]

The finding of shared genetic architecture between stimulant dependence and other psychiatric conditions is consistent with high clinical co-occurrence rates. People with ADHD are at elevated risk for substance use disorders, and genome-wide analyses now provide a biological explanation for some of this overlap: shared variants in pathways that regulate attention, reward, and impulse control contribute to both sets of conditions.

The enrichment of nicotinic acetylcholine receptor pathway genes in stimulant dependence findings aligns with evidence of shared neurobiological substrates across substance use disorders. The research base for stimulant dependence genetics is less dense than for alcohol or nicotine dependence, but the signals identified so far point toward coherent biology.[¹]

How stimulant dependence affects you

Stimulant dependence affects multiple organ systems and dimensions of daily life. Acutely, stimulants produce elevated energy, focused attention, and euphoria — precisely the qualities that make them appealing and prone to misuse. With repeated use, the brain adapts to chronically elevated dopamine by reducing receptor sensitivity in reward circuits, making natural pleasures feel less rewarding and intensifying the pull toward the substance.

Cardiovascular strain accumulates with extended use: elevated heart rate, increased blood pressure, and reduced blood vessel flexibility place ongoing stress on the heart. The prefrontal cortex — central to planning and impulse regulation — undergoes measurable changes in people with chronic stimulant dependence that can persist well into recovery. Mental health conditions including anxiety and depression frequently co-occur with stimulant dependence, partly reflecting the shared genetic architecture identified in the research literature.

Family history carries meaningful information. A first-degree relative with stimulant dependence or other substance use disorders indicates elevated inherited susceptibility. Understanding that this susceptibility has a partly biological basis can inform support strategies and help reduce stigma associated with the condition.

Working with your stimulant dependence profile

What research suggests about biology and behavioral context

Several evidence-linked factors interact with genetic background in stimulant dependence:

Genetic overlap with ADHD and anxiety — shared genetic architecture suggests these conditions are biologically linked; addressing co-occurring ADHD or anxiety with evidence-based treatment may reduce vulnerability to stimulant misuse.[¹]
Prefrontal cortex involvement — CPVL expression evidence from prefrontal tissue points to this region as a key biological mediator; protecting executive function through adequate sleep, stress management, and minimized early-life substance exposure may be protective.[¹]
Nicotinic pathway enrichment — the biological overlap between stimulant dependence and nicotine dependence at the genetic level suggests that neural circuits responsive to both substances share a common architecture.[¹]
African-ancestry individuals carry the strongest documented variant signal — the SLC25A16 locus showed the strongest genome-wide significant association in African-ancestry individuals, an important context when interpreting results across diverse ancestries.[¹]
Genetic risk is probabilistic, not deterministic — carrying a variant associated with elevated susceptibility in population research does not determine individual outcomes; social support, access to care, and environmental context all shape trajectories significantly.

The genetic architecture of stimulant dependence overlaps substantially with these related traits:

Alcohol Dependence Risk — significant genome-wide pleiotropy confirmed with stimulant dependence
ADHD Genetic Risk — shared genetic architecture documented in genome-wide analysis
Anxiety Disorder Risk — co-occurring genetic signal identified in the same research

Cross-category:

Dopamine Reward Sensitivity — overlapping reward circuit biology
Nicotine Dependence Risk — nicotinic acetylcholine receptor gene enrichment overlap

See how NRXN1 variants shape synaptic function and brain connectivity.

See our methodology page for how ExomeDNA evaluates genetic evidence.

Frequently asked questions

Is stimulant dependence genetic? Research has identified genetic variants associated with elevated susceptibility to stimulant dependence, including regions near NRXN1, GNAO1, CPVL, and SLC25A16. Genetics does not alone determine who develops the condition — environment, access to substances, co-occurring psychiatric conditions, and social context all matter substantially — but inherited biological differences do contribute measurably to individual vulnerability.[¹]

What is SLC25A16 and why does it appear in stimulant dependence research? SLC25A16 encodes a mitochondrial carrier protein that transports molecules across the inner mitochondrial membrane to support cellular energy metabolism. A variant near SLC25A16 on chromosome 10 showed the strongest genome-wide significant association with stimulant dependence in people of African ancestry in published research, with approximately 3.70× greater odds for people carrying the risk variant. How this mitochondrial gene specifically contributes to stimulant dependence biology is still being studied.[¹]

Why does genetic research show overlap between stimulant dependence and ADHD? Genome-wide analysis identified statistically significant shared genetic architecture between stimulant dependence and ADHD. Some of the same variants that contribute to ADHD risk also contribute to stimulant dependence risk. Biologically, both conditions involve dopamine signaling in prefrontal and reward-related circuits, and the genetic overlap reflects this shared neurobiology. Clinically, ADHD and stimulant use disorders co-occur at rates higher than chance, and the genome-wide findings help explain why.[¹]

Does carrying these variants mean I will develop stimulant dependence? No. Variants associated with elevated risk in population research describe average differences across large groups — they do not predict any individual's outcome. The research base for stimulant dependence genetics is moderate, meaning the field has identified real signals but has not mapped the full genetic architecture. Most people with these variants will not develop stimulant dependence, and many people who do develop it do not carry any single identified risk variant.

Is stimulant dependence risk inherited through families? Stimulant dependence shows familial clustering consistent with heritable susceptibility. Genome-wide research has identified specific inherited variants that contribute to this risk, including at loci near NRXN1, GNAO1, CPVL, and SLC25A16. The genetic overlap with alcohol dependence and ADHD also suggests shared inherited pathways across related conditions, which is why family history of any substance use disorder or psychiatric condition carries informational value.[¹]

References

[1] Cox J, et al. Genome-wide association study of stimulant dependence. Translational Psychiatry. 2021 Jun 29. PMID: 34226506.

Data sources:

GWAS Catalog (NHGRI-EBI, accessed 2026-05-29)
Open Targets Platform (CC0 1.0, accessed 2026-05-29)
ClinVar (NCBI, accessed 2026-05-29) — entries at ≥2-star review status
ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)

See our methodology page for how ExomeDNA assesses genetic evidence.

By the ExomeDNA Research Team

Browse all traits →